The company
Pulmonx Corporation
LUNG · Nasdaq
LUNG stood above a rising 150-day average in 8 of the last 52 weekly readings, including each of the last 8 weeks. It is 9.3% above that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- In trend
- Weeks in an uptrend
- 8 in a row
- Industry in uptrend
- 27% -9 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $1.0M
- Officials’ trades on record
- 0
- Institutions holding
- 103 (-3)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 8 of 52 weeks.
Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| David Aaron LehmanGeneral Counsel | sold | 3,807at $2.26 | 1 Sep 2026filed 3 Sep 2026 |
| David Aaron LehmanGeneral Counsel | sold | 2,224at $2.26 | 1 Sep 2026filed 3 Sep 2026 |
| David Aaron LehmanGeneral Counsel | sold | 3,476at $2.26 | 1 Sep 2026filed 3 Sep 2026 |
| David Aaron LehmanGeneral Counsel | sold | 4,827at $2.26 | 1 Sep 2026filed 3 Sep 2026 |
| Geoffrey Beran RoseChief Commercial Officer | sold | 2,213at $2.26 | 1 Sep 2026filed 3 Sep 2026 |
| Geoffrey Beran RoseChief Commercial Officer | sold | 2,390at $2.26 | 1 Sep 2026filed 3 Sep 2026 |
| Geoffrey Beran RoseChief Commercial Officer | sold | 1,530at $2.26 | 1 Sep 2026filed 3 Sep 2026 |
| Geoffrey Beran RoseChief Commercial Officer | sold | 1,746at $2.26 | 1 Sep 2026filed 3 Sep 2026 |
| Glendon E. French IIIPresident and CEO | sold | 4,098at $2.26 | 1 Sep 2026filed 3 Sep 2026 |
| Glendon E. French IIIPresident and CEO | sold | 37,784at $2.26 | 1 Sep 2026filed 3 Sep 2026 |
| Srikanth RadhakrishnanChief Science & Techn. Officer | sold | 2,643at $2.26 | 1 Sep 2026filed 3 Sep 2026 |
| Srikanth RadhakrishnanChief Science & Techn. Officer | sold | 2,121at $2.26 | 1 Sep 2026filed 3 Sep 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| PRIMECAP MANAGEMENT COreduced · filed 14 Aug 2026 | 4,612,331$6.0M | -112,660−2.4% |
| MORGAN STANLEYreduced · filed 13 Aug 2026 | 2,922,921$3.8M | -1,070,641−26.8% |
| Soleus Capital Management, L.P.unchanged · filed 11 Aug 2026 | 2,788,323$3.6M | 00.0% |
| VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026 | 1,630,219$2.1M | -4,045−0.2% |
| ExodusPoint Capital Management, LPreduced · filed 14 Aug 2026 | 1,223,555$1.6M | -720,279−37.1% |
| Almitas Capital LLCnew · filed 17 Aug 2026 | 1,064,202$1.4M | +1,064,202 |
| BlackRock, Inc.reduced · filed 7 Aug 2026 | 882,490$1.1M | -1,779,117−66.8% |
| Stonepine Capital Management, LLCadded · filed 14 Aug 2026 | 815,436$1.1M | +47,148+6.1% |
| JANE STREET GROUP, LLCadded · filed 14 Aug 2026 | 758,231$986K | +624,961+468.9% |
| BRAIDWELL LPunchanged · filed 14 Aug 2026 | 752,541$978K | 00.0% |
News
No headline names it lately.
Everyone who traded it
Same industry
Government contracts
From its SEC filings
Analyst forecasts
No analyst forecasts yet.